Medically Challenging Case Abstract
ACAAI 2020 Annual Scientific Meeting
The Changing Practice Landscape - RISING to the CHALLENGE
Submission Deadline: August 2, 2020
Medically Challenging Cases (MCC)
The College invites you to submit an abstract for the 2020 Annual Scientific Meeting, November 12-16 in Phoenix. The theme of the meeting is: The Changing Practice Landscape - RISING to the CHALLENGE.
New for 2020!
Medically Challenging Case Submission
The deadline for case submission is 11:59 PM (CDT) on August 2, 2020. Cases must be submitted electronically via the online form, and they must be complete, including the author listing. ACAAI will not accept any cases or changes to cases after the submission deadline. Case changes include: changes to title or body, changes to presenting authors, author additions, revised author names, and/or revised author listing. This deadline applies to ALL Medically Challenging Case abstract submissions.
There is a $60 non-refundable fee for each abstract submission. Payment does not guarantee that the abstract will be accepted. Payment must be made by credit card (Visa, MasterCard or American Express). Purchase orders and checks will not be accepted.
Medically Challenging Case (MCC) Presentations
If the Presenting Author wishes to withdraw his/her case from the Annual Meeting program, a written request must be submitted to firstname.lastname@example.org by August 2, 2020. Any request for withdrawal after that date cannot be assured removal from the ACAAI's official journal, the Annals of Allergy & Immunology or other ACAAI Annual Meeting publications or references.
Abstract Author Disclosure of Financial Relationships
Abstracts may be submitted by fellows, members and non-members of the College. Employees of pharmaceutical or medical device companies or other ACCME-defined commercial interests are prohibited from participating as an author or presenter of an oral abstract; however, they may participate as an author or presenter for the poster session.
An ACCME-defined commercial interest is, “any entity producing, marketing, reselling or distributing healthcare goods or services used on, or consumed by, patients.”
All authors must complete the online Disclosure of Financial Relationships by August 2, 2020 or their names will be pulled as an abstract author.
Disclosure of relevant financial relationships includes the commercial interest name, the role played, and what was received.
The ACCME has not set a minimum dollar amount for relationships to be considered relevant and does not use the term significant to describe financial relationships. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All abstracts must be devoid of commercial bias. Trade names should not be used in referencing drugs, devices or instrumentation. Any medications or other substances referred to in the presentation material should be identified by their generic name or description. Trade name violations/commercial bias will result in below average scores or rejection. Failure to disclose financial relationships with ACCME-defined commercial interests will prohibit an author/presenter from participating in oral and poster sessions.
HERE'S WHAT YOU WILL NEED TO SUBMIT FOR EACH AUTHOR:
ORGANIZATION OF ABSTRACT BODY
There is a limit of 15 words for the title and 250 words for the body of your abstract submission.
Each abstract should contain:
Submitting a COVID-19 abstract? Please read the following:
Be sure to use "Introduction", "Case Description" and "Discussion" in the body of your abstract to indicate the start of each new section. The abstract title and author information should not be included in the body of the abstract.
Best results are achieved copying and pasting directly from a Word document. Please make sure that you use the "Insert Symbols" feature in Word for any mathematical, Latin or scientific expressions. If you are entering the copy directly onto the Abstract Form, you must use the “Symbols” icon to ensure your result is displayed accurately. Always verify that your information is correct prior to submitting by selecting "Print Preview."
Capitalize only the first letter of each word of the title. Do not use formatting tags in the title. The title will be formatted automatically by the system at the time of print production. Abbreviations must not be used in the title.
Editorial Policies for Authors (ICMJE Guidance)
Reproduced Materials - When previously published figures or tables are used, the author must obtain written permission from the copyright holder (usually the publisher) to reproduce the material in print and online. An appropriate credit line should be included in the figure legend or table footnote, and full publication information should be cited in the reference list. Letters of permission must accompany the manuscript at the time of submission.
All abstracts must be devoid of commercial bias. Trade names should not be used in referencing drugs, devices or instrumentation. Any medications or other substances referred to in the presentation material should be identified by their generic name or description. Trade name violations/commercial bias will result in below average scores or rejection.
Use of Figures
You may add one figure to your abstract, however, it is recommended that results be shown in narrative form, since figure formats may be compromised in publication. The figure must be submitted as a jpg file and cannot exceed 500kb.
Medically Challenging Case Acceptance
If the abstract is accepted for presentation at the 2020 ACAAI Annual Meeting, the submitting author will be notified via email in early September. Only the submitting author will be notified of abstract programming. Please make sure all contact information is accurate. The notification will include the scheduled date, time and location of the presentation.
For your convenience, all accepted posters for the 2020 ACAAI Annual Meeting will be displayed electronically. Complete details regarding the electronic posters will be sent to the submitting author of accepted abstracts in early September. Abstracts scheduled for presentation will be grouped by topic, numbered and listed in the program and published in the ACAAI'S official journal, the Annals of Allergy, Asthma and Immunology abstract supplement. The decision of the ACAAI Abstract Review Subcommittee regarding acceptance and presentation of abstracts is final.
All authors who will be attending the Annual Meeting must register online for the meeting and pay any applicable registration fees. The meeting registration site will open in August.
Back to Top